Clinical trial NCT04820803: Assessment of the Impact of Oral Intervention With Cetylpyridinium Chloride to Decrease SARS-CoV-2 Viral Load in Patients With COVID-19
Official title: PILOT CLINICAL TRIAL TO ASSESS THE IMPACT OF ORAL INTERVENTION WITH CETIL PYRIDINIUM CHLORIDE TO REDUCE THE VIRAL LOAD OF SARS-CoV-2
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID-19
SARS-CoV-2 Infection
Keywords: cetylpyridinium
SARS-CoV-2
COVID-19
mouthwashes
Lead sponsor: Instituto de Investigación Sanitaria Aragón
Sponsor class: OTHER
Collaborators: name: Dentaid SL
First posted: 2021-03-29
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a bilateral contrast, 40 subjects in the first group and 40 in the second were required to detect a difference equal to or greater than 5 units. The common standard deviation is assumed to be 10 (12). A loss to follow-up rate of 20% has been estimated.
Primary purpose: PREVENTION

Brief summary: Pilot, randomized and controlled clinical trial for the evaluation of the decrease in the viral load of SARS-CoV-2 in the oropharynx in patients with COVID-19 through the use of mouthwash containing cetylpyridinium chloride (CPC) (0.07%) in mouthwash.

Detailed description: The objective of the clinical trial is to determine the short-term efficacy of cetylpyridinium chloride (CPC) mouthwashes to assess changes in the threshold cycle value of the analysis of the SARS-CoV-2 oropharyngeal saliva sample, in patients diagnosed with COVID-19 and with symptomatology compatible with the disease. A randomized double-blind pilot clinical trial (evaluator and patients) will be developed in patients with a diagnosis of COVID-19 and symptoms of the disease. The experimental group will perform a single rinse with a mouthwash containing Cetylpyridinium Chloride (CPC) while the placebo group will perform the same rinse, but with a harmless liquid that will act as a placebo. The study will be carried out in the Zaragoza III Health Sector, with patients belonging to the Zaragoza II Health Sector, collaborating with the "Seminario" health center and the Lozano Blesa Clinical University Hospital (HCULB). This project will be carried out in accordance with the CONSORT guidelines for clinical trials.

Eligibility criteria: Inclusion Criteria:

* Outpatients older than 18 years and younger than 80 years.
* Patients with a medical indication for a diagnostic test for active infection to SARS-CoV-2
* Patients who present mild symptoms typical of COVID-19 and who have less than three days of evolution
* Patients who have cognitive and motor skills to perform mouthwash correctly.
* Patients who understand and speak Spanish
* Patients who freely give their consent to participate in the study, after a correct understanding of its objectives and procedures.

Exclusion Criteria:

* Patients with hospitalization criteria (moderate or severe symptoms)
* Vulnerable populations such as pregnant, lactating,
* Patients with recent medical diagnosis (≤ 1 month) of pneumonia
* Patients with hyposialia
* Patients with consumption of oral antiseptics (in the form of mouthwash containing CPC, povidone iodine rinses, alcohol mouthwash and essential oils) and toothpastes with CPC during the last month.
* Patients with cognitive impairment

Primary outcomes:
measure: Threshold cycle value of SARS-CoV-2 by Polymerase Chain Reaction (PCR) in saliva samples
timeFrame: 3 months
measure: SARS-CoV-2 Nucleocapsid protein in saliva by ELISA
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Zaragoza
country: Spain
facility: Seminario Health Center and Lozano Blesa University Clinical Hospital
Study officials:
References: